Table 3 Comparison between adult and children LCH
From: Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study
| Â | Adolescent (current study) | Adult (PUMCH) | Children (China) | P1 | P2 |
|---|---|---|---|---|---|
Sex | |||||
Male, (%) | 25 (69.4) | 177 (66.5) | 49 (51.6) | 0.728 | 0.074 |
Organ involvement | Â | Â | Â | Â | Â |
SS-s, (%) | 10 (27.8) | 40 (15.0) | 26 (27.3) | 0.054 | 1 |
SS-p, (%) | 2 (5.6) | 18 (6.8) | 0 (0) | 1 | 0.075 |
SS-m, (%) | 5 (13.9) | 26 (9.8) | 24 (25.2) | 0.392 | 0.154 |
MS, (%) | 19 (52.8) | 182 (68.4) | 44 (46.3) | 0.062 | 0.542 |
&MS organ involvement | |||||
Pituitary, (%) | 15 (78.9) | 112 (61.5) | 8 (18.2) | 0.134 |  < 0.001 |
Bone, (%) | 8 (42.1) | 127 (69.8) | 28 (63.6) | 0.015 | 0.113 |
Lung, (%) | 8 (42.1) | 111 (61.0) | 17 (38.6) | 0.111 | 0.796 |
Lymph node, (%) | 8 (42.1) | 64 (35.2) | 17 (38.6) | 0.548 | 0.796 |
Liver, (%) | 6 (31.6) | 42 (23.1) | 17 (38.6) | 0.405 | 0.593 |
Spleen, (%) | 6 (31.6) | 15 (8.2) | 9 (20.5) | 0.007 | 0.353 |
Thyroid, (%) | 5 (26.3) | 25 (13.7) | Â | Â | Â |
Skin, (%) | 3 (15.8) | 48 (26.4) | 22 (50.0) | 0.413 | 0.011 |
Haematopoietic system, (%) | 0 (0) | 0 (0) | 9 (20.5) | 1 | 0.047 |
Risk organ, (%) | 8 (42.1) | 47 (25.8) | 20 (45.5) | 0.13 | 0.806 |
Genomic profiling | |||||
BRAFV600E, (%) | 1 (10.0) | 26 (38.8) | 48 (57.1) | 0.090 | 0.006 |
BRAF deletion, (%) | 5 (50.0) | 17 (25.4) | 2 (2.4) | 0.138 |  < 0.001 |
MAP2K1, (%) | 1 (10.0) | 13 (19.4) | 1 (1.2) | 0.679 | 0.202 |
Outcomes | |||||
Reactivation rate (%) | *SS-s 33.3% | *SS-s 27.5% | Â | 0.696 | NA |
SS 23.5% | Â | SS 12.0% | NA | 0.249 | |
SS-m/MS 37.5% | SS-m/MS 45.8% | Â | 0.441 | NA | |
MS 47.4% | Â | MS 15.9% | NA | 0.008 | |
EFS (%) | 3-y EFS SS-s 87.5% SS-m/MS 69.0% | 3-y EFS SS-s 63.3% SS-m/MS 54.7% | 5-y EFS 74.6% | Â | Â |